TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

Subscribe today! Click here for our subscription offers.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Profit increases 12% at Dick’s Sporting Goods
  2. Oakland firm Qualaris Healthcare’s software saves time in hospitals
  3. Lower tax rate to help Mylan extend buying spree
  4. Construction picks up, but workers hard to find
  5. Lumber Liquidators shares plunge 25%
  6. Consumer spending dinged by declining gas prices
  7. PNC Bank to cut financing of mountaintop removal coal companies
  8. Pittsburgh gas pump prices up nearly 9 cents
  9. Shift in what powers the grid raises concerns about fuel diversity
  10. Rue21 adjusts for tough market
  11. Highmark lays off nearly 100 workers, mostly in IT, as membership declines